PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-11.70%
Cash & equivalents declining -11.70% while Medical - Pharmaceuticals shows 0.00% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
100.00%
Short-term investments yoy growth ≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt might see stronger near-cash accumulation as an opportunity. Check yields vs. peers.
-11.70%
Cash + STI yoy growth ≥ 1.5x the Medical - Pharmaceuticals median of -6.86%. Joel Greenblatt would see a liquidity advantage if effectively redeployed.
-25.00%
Receivables growth above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a serious red flag in ballooning receivables.
0.29%
Inventory growth less than half of Medical - Pharmaceuticals median of 6.52%. Joel Greenblatt might see well-managed stock levels if revenue is fine.
43.75%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
-4.32%
Current assets growth ≥ 1.5x the Medical - Pharmaceuticals median of -2.59%. Joel Greenblatt sees a potential liquidity edge if well allocated.
0.11%
PP&E growth below half of Medical - Pharmaceuticals median of -0.08%. Jim Chanos would suspect potential underinvestment or strategic shift away from core assets.
No Data
No Data available this quarter, please select a different quarter.
-4.85%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
-4.85%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see big intangible expansions as a red flag for future impairments.
19.08%
≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees a bigger push into long-term investments. Check synergy with core business.
-1314.36%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees large expansions in deferred tax assets, possibly pointing to bigger NOLs.
1043.15%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
-0.00%
Below half the Medical - Pharmaceuticals median of -0.11%. Jim Chanos sees a sharp divergence from peers, possibly a sign of strategic retreat or capital shortage.
-25.00%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees potential red flags in big "other" asset lumps.
-1.54%
≥ 1.5x the Medical - Pharmaceuticals median of -0.75%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
-4.68%
Payables growth above 1.5x Medical - Pharmaceuticals median of -0.37%. Jim Chanos might see a warning sign of stressed supplier payments.
No Data
No Data available this quarter, please select a different quarter.
-55.78%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
-80.39%
Below half Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potential sales pipeline shortfall.
261.61%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
-6.70%
Below half Medical - Pharmaceuticals median of 0.03%. Joel Greenblatt sees more conservative short-term leverage than peers.
-6.66%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
94.68%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potentially alarming surge in other LT obligations.
-3.08%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
-6.44%
Below half Medical - Pharmaceuticals median of 0.60%. Joel Greenblatt sees a much lower liability expansion vs. peers.
No Data
No Data available this quarter, please select a different quarter.
4.59%
Below half Medical - Pharmaceuticals median of -3.18%. Jim Chanos suspects poor profitability or large dividend drains.
6.78%
Above 1.5x Medical - Pharmaceuticals median 0.00%. Jim Chanos suspects a red flag if these gains are highly volatile.
-100.00%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potential red flag for complicated equity transactions.
4.33%
Below half Medical - Pharmaceuticals median of -1.81%. Jim Chanos suspects slower net worth growth or losses vs. peers.
-1.54%
≥ 1.5x Medical - Pharmaceuticals median of -0.54%. Joel Greenblatt sees more aggressive expansions than peers.
405740.00%
Below half Medical - Pharmaceuticals median of -1.13%. Jim Chanos sees potential underinvestment or forced liquidation vs. peers.
-44.81%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
1.66%
50-75% of Medical - Pharmaceuticals median 2.25%. Mohnish Pabrai notes comparatively lower net debt growth.